Evaluation of a Personalised Survivorship Care Plan App for Patients With Melanoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorErasmus Medical Center
About this trial
A multicentre randomised controlled trial (RCT) will be conducted to evaluate the effectiveness of the digital personalised Melanoma Survivorship Care Plan (SCP) app. A total of hundred-eighty melanoma patients (stage I and II) will be randomised to receive either the SCP Melanoma app or usual care. The app provides survivors with personalized healthcare information on diagnosis, treatment and follow-up and supportive care, tailored to their melanoma stage and phase and information needs.Through questionnaires, medical file records, patient-reported outcomes and use of medical care will be evaluated. In addition, log-data, questionnaires and interviews will be used to evaluate the process of the uptake and implementation of the digital SCP.
Eligibility criteria
Qualifiers
18 years or older
Patients who have received a primary diagnosis of cutaneous melanoma stage I to II in the past 0-4 months
Disqualifiers
Patients with irresectable stage III melanoma, patients receiving neo-adjuvant treatment and patients with stage IV melanoma.
Patients who do not have (sufficient) command of the Dutch language.
Trial design
Treatments tested in this trial
- Digizorg Melanoma app
Treatment groups
180 Participants
are divided into 2 treatment groupsSponsors and collaborators
Erasmus Medical Center
Lead sponsor
BeterKeten
Collaborator
Albert Schweitzer Hospital
Collaborator
Maasstad Hospital
Collaborator
Franciscus Gasthuis
Collaborator
Source ClinicalTrials.gov